ATXS
Astria Therapeutics, Inc.
Biotechnology
Market Cap$718M
5Y Perf.-66.2%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ATXS vs KALV
Revenue, margins, valuation, and 5-year total return — side by side.
KALV
KalVista Pharmaceuticals, Inc.
Biotechnology
Market Cap$1.37B
5Y Perf.+43.6%
ATXS vs KALV — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ATXS | KALV |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $718M | $1.37B |
| Revenue (TTM) | $706K | $15M |
| Net Income (TTM) | $-124M | $-210M |
| Gross Margin | 100.0% | -17.2% |
| Operating Margin | -193.4% | -13.4% |
| Total Debt | $5M | $6M |
| Cash & Equiv. | $60M | $99M |
ATXS vs KALV — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ATXS
KALV
| Stock | May 20 | Jan 26 | Return |
|---|---|---|---|
| Astria Therapeutics… (ATXS) | 100 | 33.8 | -66.2% |
| KalVista Pharmaceut… (KALV) | 100 | 143.6 | +43.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ATXS vs KALV
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ATXS leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and recent price momentum and sentiment. KalVista Pharmaceuticals, Inc. is the stronger pick specifically for profitability and margin quality and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
ATXS
Astria Therapeutics, Inc.
The Growth Play
ATXS carries the broadest edge in this set and is the clearest fit for growth exposure and sleep-well-at-night.
- EPS growth 30.6%
- Lower volatility, beta 1.32, Low D/E 1.7%, current ratio 17.49x
- -21.7% revenue growth vs KALV's -34.5%
Best for: growth exposure and sleep-well-at-night
KALV
KalVista Pharmaceuticals, Inc.
The Income Pick
KALV is the clearest fit if your priority is income & stability and long-term compounding.
- beta 0.82
- 156.2% 10Y total return vs ATXS's -95.2%
- Beta 0.82, current ratio 5.35x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ATXS | -21.7% revenue growth vs KALV's -34.5% |
| Quality / Margins | KALV | -13.9% margin vs ATXS's -175.7% |
| Stability / Safety | KALV | Beta 0.82 vs ATXS's 1.32 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ATXS | +187.9% vs KALV's +113.9% |
| Efficiency (ROA) | ATXS | -45.6% ROA vs KALV's -77.7%, ROIC -50.3% vs -152.3% |
ATXS vs KALV — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLKALVLAGGINGATXS
ATXSAstria Therapeutics, …
2leads
KALVKalVista Pharmaceutic…
3leads
6 Total Categories
CATEGORYLEADERvs ATXSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
KALV4/5
Valuation MetricsMultiples, price ratios, and targets
ATXS2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ATXS6/8
Total Returns1Y, 3Y, 5Y total returns with dividends
KALV4/6
Risk & VolatilityBeta, volatility, and downside exposure
KALV2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
KALV leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
KALV is the larger business by revenue, generating $15M annually — 21.4x ATXS's $706,000. KALV is the more profitable business, keeping -13.9% of every revenue dollar as net income compared to ATXS's -175.7%.
| Metric | ATXSAstria Therapeuti… | KALVKalVista Pharmace… |
|---|---|---|
| RevenueTrailing 12 months | $706,000 | $15M |
| EBITDAEarnings before interest/tax | -$134M | -$202M |
| Net IncomeAfter-tax profit | -$124M | -$210M |
| Free Cash FlowCash after capex | -$120M | -$160M |
| Gross MarginGross profit ÷ Revenue | +100.0% | -17.2% |
| Operating MarginEBIT ÷ Revenue | -193.4% | -13.4% |
| Net MarginNet income ÷ Revenue | -175.7% | -13.9% |
| FCF MarginFCF ÷ Revenue | -170.4% | -10.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -27.9% | -1.1% |
KALV leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
ATXS leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | ATXSAstria Therapeuti… | KALVKalVista Pharmace… |
|---|---|---|
| Market CapShares × price | $718M | $1.4B |
| Enterprise ValueMkt cap + debt − cash | $664M | $1.3B |
| Trailing P/EPrice ÷ TTM EPS | -7.49x | -7.24x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 2.21x | 13.91x |
| Price / FCFMarket cap ÷ FCF | — | — |
ATXS leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
ATXS leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
ATXS delivers a -53.2% return on equity — every $100 of shareholder capital generates $-53 in annual profit, vs $-3 for KALV. ATXS carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to KALV's 0.07x. On the Piotroski fundamental quality scale (0–9), KALV scores 2/9 vs ATXS's 1/9, reflecting mixed financial health.
| Metric | ATXSAstria Therapeuti… | KALVKalVista Pharmace… |
|---|---|---|
| ROE (TTM)Return on equity | -53.2% | -2.8% |
| ROA (TTM)Return on assets | -45.6% | -77.7% |
| ROICReturn on invested capital | -50.3% | -152.3% |
| ROCEReturn on capital employed | -39.4% | -89.9% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 2 |
| Debt / EquityFinancial leverage | 0.02x | 0.07x |
| Net DebtTotal debt minus cash | -$54M | -$92M |
| Cash & Equiv.Liquid assets | $60M | $99M |
| Total DebtShort + long-term debt | $5M | $6M |
| Interest CoverageEBIT ÷ Interest expense | — | -13.75x |
ATXS leads this category, winning 6 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
KALV leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ATXS five years ago would be worth $10,977 today (with dividends reinvested), compared to $10,783 for KALV. Over the past 12 months, ATXS leads with a +187.9% total return vs KALV's +113.9%. The 3-year compound annual growth rate (CAGR) favors KALV at 41.0% vs ATXS's -0.1% — a key indicator of consistent wealth creation.
| Metric | ATXSAstria Therapeuti… | KALVKalVista Pharmace… |
|---|---|---|
| YTD ReturnYear-to-date | -2.4% | +72.8% |
| 1-Year ReturnPast 12 months | +187.9% | +113.9% |
| 3-Year ReturnCumulative with dividends | -0.4% | +180.1% |
| 5-Year ReturnCumulative with dividends | +9.8% | +7.8% |
| 10-Year ReturnCumulative with dividends | -95.2% | +156.2% |
| CAGR (3Y)Annualised 3-year return | -0.1% | +41.0% |
KALV leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
KALV leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
KALV is the less volatile stock with a 0.82 beta — it tends to amplify market swings less than ATXS's 1.32 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KALV currently trades 99.5% from its 52-week high vs ATXS's 94.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ATXSAstria Therapeuti… | KALVKalVista Pharmace… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.32x | 0.82x |
| 52-Week HighHighest price in past year | $13.29 | $26.84 |
| 52-Week LowLowest price in past year | $3.69 | $9.83 |
| % of 52W HighCurrent price vs 52-week peak | +94.7% | +99.5% |
| RSI (14)Momentum oscillator 0–100 | 46.1 | 75.4 |
| Avg Volume (50D)Average daily shares traded | 1.6M | 3.0M |
KALV leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates ATXS as "Hold" and KALV as "Buy". Consensus price targets imply 54.2% upside for ATXS (target: $19) vs 6.7% for KALV (target: $29).
| Metric | ATXSAstria Therapeuti… | KALVKalVista Pharmace… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $19.40 | $28.50 |
| # AnalystsCovering analysts | 8 | 13 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
KALV leads in 3 of 6 categories (Income & Cash Flow, Total Returns). ATXS leads in 2 (Valuation Metrics, Profitability & Efficiency).
Best OverallKalVista Pharmaceuticals, I… (KALV)Leads 3 of 6 categories
Loading custom metrics...
ATXS vs KALV: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ATXS or KALV a better buy right now?
Analysts rate KalVista Pharmaceuticals, Inc.
(KALV) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ATXS or KALV?
Over the past 5 years, Astria Therapeutics, Inc.
(ATXS) delivered a total return of +9. 8%, compared to +7. 8% for KalVista Pharmaceuticals, Inc. (KALV). Over 10 years, the gap is even starker: KALV returned +156. 2% versus ATXS's -95. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ATXS or KALV?
By beta (market sensitivity over 5 years), KalVista Pharmaceuticals, Inc.
(KALV) is the lower-risk stock at 0. 82β versus Astria Therapeutics, Inc. 's 1. 32β — meaning ATXS is approximately 61% more volatile than KALV relative to the S&P 500. On balance sheet safety, Astria Therapeutics, Inc. (ATXS) carries a lower debt/equity ratio of 2% versus 7% for KalVista Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — ATXS or KALV?
On earnings-per-share growth, the picture is similar: Astria Therapeutics, Inc.
grew EPS 30. 6% year-over-year, compared to -7. 3% for KalVista Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ATXS or KALV?
KalVista Pharmaceuticals, Inc.
(KALV) is the more profitable company, earning -1391. 1% net margin versus -175. 7% for Astria Therapeutics, Inc. — meaning it keeps -1391. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KALV leads at -1343. 0% versus -193. 4% for ATXS. At the gross margin level — before operating expenses — ATXS leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ATXS or KALV?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ATXS or KALV better for a retirement portfolio?
For long-horizon retirement investors, KalVista Pharmaceuticals, Inc.
(KALV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 82), +156. 2% 10Y return). Both have compounded well over 10 years (KALV: +156. 2%, ATXS: -95. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ATXS and KALV?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.